BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).
Jeffrey Alan Sosman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Bristol-Myers Squibb
Adil Daud
No relevant relationships to disclose
Jeffrey S. Weber
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Kevin Kim
Research Funding - GlaxoSmithKline
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline
Keith Flaherty
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jeffrey R. Infante
Consultant or Advisory Role - GlaxoSmithKline (U)
Omid Hamid
Research Funding - GlaxoSmithKline
Jonathan S. Cebon
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Lynn Mara Schuchter
Research Funding - GlaxoSmithKline
Robert R. McWilliams
No relevant relationships to disclose
Mario Sznol
Consultant or Advisory Role - BeiGene; Bristol-Myers Squibb; Nektar
William Howard Sharfman
Consultant or Advisory Role - Merck
Alain Patrick Algazi
Research Funding - GlaxoSmithKline
Karl D. Lewis
Research Funding - GlaxoSmithKline
Shonda M Little
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Georgina Long
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Roche
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline (B)
Rene Gonzalez
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche